Ligelizumab

Drug Profile

Ligelizumab

Alternative Names: QGE-031

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Tanox
  • Developer Novartis
  • Class Allergens; Antiallergics; Antiasthmatics; Food allergy immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Bullous pemphigoid; Urticaria
  • Phase I Hypersensitivity
  • Suspended Atopic dermatitis

Most Recent Events

  • 01 Mar 2016 Novartis Pharmaceuticals initiates enrolment in a phase II extension study for Urticaria in USA (NCT02649218)
  • 01 Mar 2016 Novartis completes a phase II trial in Asthma in USA, Belgium, Canada, France, Germany, Hungary, Italy, Japan, Netherlands and Slovakia (NCT02336425)
  • 09 Jan 2016 Novartis Pharmaceuticals plans a phase II extension study for Urticaria in USA (NCT02649218)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top